DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients

Information source: Clinique Neuro-Outaouais
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Multiple Sclerosis

Intervention: Observational Cognitive assessments (Other); noninterventional, cognitive testing in tysabri treated patients (Other)

Phase: Phase 4

Status: Completed

Sponsored by: Clinique Neuro-Outaouais

Official(s) and/or principal investigator(s):
François H Jacques, MD, Principal Investigator, Affiliation: Clinique Neuro-Outaouais and Centre de Santé et de Services Sociaux de Gatineau, Hôpital de Hull


This study is designed to evaluate the effect of Tysabri on cognition in multiple sclerosis (MS) patients. During a period of 24 months, the study will assess the evolution of cognitive function in Tysabri treated MS patients using the Symbol Digit Modalities Test (SDMT) and the CogState battery of tests.

Clinical Details

Official title: Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: SDMT CogState battery

Detailed description: Tysabri reduces the relapse frequency, slows progression and preserves cognitive function as compared to placebo as per the AFFIRM trial. The benefit on relapse rate and progression appears to be sustained in longer-term studies such as STRATA. In clinical practice however despite a stable condition on the Expanded Disability Status Scale (EDSS) patients often complain of cognitive deterioration. It has yet to be shown that Tysabri will prevent cognitive deterioration after more than 2 years of treatment. The Symbol Digit Modalities Test (SDMT) is a sensitive and validated test of cognition in MS. CogState offers a standardized battery of cognitive tests frequently used in clinical research in the fields of dementia and Parkinson's disease. The CogState battery of tests consisting of the Detection test (processing speed), Identification test (attention), One Back test (working memory), International Shopping List test (verbal learning) and the Groton Maze Learning test (reasoning and problem solving) will further confirm and validate the results of the Symbol Digit Modalities Test(SDMT) in MS patients as well as examine other cognitive parameters. Together the above tests done prospectively can assess the evolution of cognitive function in Tysabri treated MS patients over the longer term.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Patients with multiple sclerosis who are receiving Tysabri per indication and are

willing and able to give an informed consent. Exclusion Criteria:

- Patients who are depressed as per the Beck depression questionnaire at screening or

at any time during the study.

- Patients with cognitive decline from causes other than MS.

Locations and Contacts

Clinique Neuro-Outaouais, Gatineau, Quebec J9J 0A5, Canada
Additional Information

Starting date: September 2011
Last updated: March 30, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017